Acute Lymphoblastic Leukemia (ALL) clinical trials in New Jersey
15 active Acute Lymphoblastic Leukemia (ALL) trials with a site in New Jersey. Describe your situation to see which ones look like a fit.
- A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia
- A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
- A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)
- A Phase 1/3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA-2)
- A Study of Revumenib and Mezigdomide in People With Leukemia
- A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies
- A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia
- Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Bright Ideas - CIN Feasibility Study
- First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.